News | May 30, 2007

AHA Aims at Swifter STEMI Rescue, Treatments

May 31, 2007 - The American Heart Association is launching a community-based program to reduce the toll of the deadliest kind of heart attack: an ST-elevation myocardial infarction (STEMI).

The total blockage of a coronary artery is fatal unless treated quickly — within 30 minutes for clot-dissolving drug treatment, and within 90 minutes for angioplasty.

But, the “HealthDay Reporter” writes today, fewer than half of all STEMI patients get the right treatment at the right time, according to Dr. Alice Jacobs, professor of medicine at Boston University and past president of the heart association, who described what the association is calling "Mission Lifeline."

The program's emphasis will be to improve on the current treatment statistics, Jacobs said. "Thirty percent of STEMI patients do not get clot-busting drugs," she said. "Twenty percent are not candidates for clot-busting drugs and, of these, 70 percent do not get angioplasty."

A major part of the effort will be devoted to establishing systems to transport STEMI patients to hospitals that are equipped to do angioplasty. The reason: "Angioplasty is better than clot-busting treatment, even when transportation is needed," Jacobs said. Only 25 percent of U.S. hospitals have the catheterization facilities that allow them to do emergency angioplasties, she said.

But another major component of the program will be devoted to teaching people in general to call 911 for emergency help when they experience symptoms of a heart attack. About half of all heart-attack patients now drive themselves to a hospital or are driven.

That adds up to a shocking loss of time when they could be getting emergency therapy, and the hospital could be preparing for their arrival, said Dr. Tim Henry, director of research at the Minneapolis Heart Institute.

The institute has a program that the heart association hopes will be a model for rural areas. It ties together more than 100 hospitals, most of which cannot do angioplasty. There had been doubts about whether patients could be transferred quickly enough for angioplasty to be done on time. But, Henry said, "We now have 31 hospitals trained up to 60 miles away, then out to 210 miles away. A 60-mile transfer can be done in 95 minutes, and a 200-mile transfer can be done in 120 minutes."

"The mortality of these patients is now 4 percent," Henry added, a figure that is impressive, because 15 percent of those transferred are over 80 years of age.

Comparable local programs in areas such as North Carolina and California also can serve as models, Jacobs said. Those programs were taken into consideration at a three-day conference in March where experts agreed on starting the nationwide effort. Details of the conference are published in the May 30 online edition of the heart association journal Circulation.

The program will start with individuals at risk of a heart attack, Henry and Jacobs said. It's important for those people to seek trained help as quickly as possible by calling 911, Jacobs said.

There are no estimates of how much the program will cost or where the money will come from, but there is the potential for saving money as well as lives, Henry said. Quick, appropriate treatment can translate into shorter hospital stays and reduced need for expensive medical technology such as implanted defibrillators, he said.

Only 3 percent of people treated in the Minneapolis program get defibrillators, Henry said.

For more information visit www.americanheart.org

Related Content

Gore Molding & Occlusion Balloon for Endovascular Aortic Repair Receives FDA Approval
Technology | Balloon Catheter | August 23, 2018
W. L. Gore & Associates Inc. (Gore) announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the Gore...
Cardiovascular Systems Inc. and OrbusNeich Announce FDA Clearance  of Sapphire II Pro 1mm Coronary Balloon
Technology | Balloon Catheter | March 21, 2018
Cardiovascular Systems Inc. (CSI) recently announced that the U.S. Food and Drug Administration (FDA) has granted 510(k...
Cardiovascular Systems Expands Product Portfolio for Peripheral and Coronary Interventions
News | Balloon Catheter | January 24, 2018
Cardiovascular Systems Inc. recently announced two new partnerships broadening the company’s product portfolio. CSI is...
Abbott recalls its NC Balloon catheters
News | Balloon Catheter | May 22, 2017
May 22, 2017 — Abbott Vascular has initiated a voluntary recall of specific lots of three catheters due to 19 reports
Videos | Balloon Catheter | November 16, 2016
A discussion with Todd Brinton, M.D., about the newly FDA-cleared Shockwave Medical Lithoplasty System, at the Transc
NuCryo Vascular, Next Generation Cryoplasty Inflation Device, PolarCath Balloon Dilatation System

PolarCath Balloon Dilatation System image courtesy of NuCryo Vascular

Technology | Balloon Catheter | March 28, 2016
NuCryo Vascular LLC announced the launch of the Next Generation Cryoplasty Inflation device. The device received U.S....
NuCryo Vascular, FDA clearance, next-gen, PolarCath System, cryoplasty inflation device
Technology | Balloon Catheter | January 12, 2016
NuCryo Vascular LLC announced that they have received U.S. Food and Drug Administration (FDA) 510(k) clearance on the...
Videos | Balloon Catheter | October 30, 2015
Todd Brinton, M.D., clinical associate professor and consulting associate professor of bioengineering at Stanford Uni
Overlay Init